Table 1.
Baseline characteristics of study patients.
| Characteristics | Total (N = 231) |
|---|---|
| Age, median (range) | 66 [37–86] |
| < 65 | 108 (46.8%) |
| 65–74 | 76 (32.9%) |
| ≥ 75 | 47 (20.4%) |
| Sex (%) | |
| Male | 186 (78.5%) |
| ECOG (%) | |
| 0 | 40 (17.2%) |
| 1 | 132 (56.9%) |
| ≥ 2 | 60 (24.8%) |
| Smoking (ever) (%) | 183(79.6%) |
| Stage | |
| IV | 231 (100%) |
| EGFR activating mutation (%) | 24 (9.9%) |
| Tumor histologic type (%) | |
| Adenocarcinoma | 125 (54.1%) |
| Squamous | 56 (24.2%) |
| Other NSCLC | 50 (21.6%) |
| PD-L1 expression level (%) | |
| ≥ 1% | 182 (78.8%) |
| Line of ICIs used (%) | |
| 1st | 40 (17.3%) |
| 2nd | 73 (31.6%) |
| 3rd or more | 118 (51.1%) |
| Type of ICIs (%) | |
| Nivolumab | 174 (75.3%) |
| Pembrolizumab | 54 (23.4%) |
| Atezolizumab | 3 (1.3%) |
| Objective response (OR) (%) | 70 (30.3%) |
| Progression (%) | 138 (59.7%) |
| PLC, /µL | |
| Pre-treatment, median [IQR] | 1525.9 [1041.9–2070] |
| Post-treatment, median [IQR] | 1676.7 [1178.6–2190] |
OR, partial response and complete response; PLC, peripheral lymphocyte count.